REGORAFENIB

作品数：35被引量：104H指数：6
导出分析报告
相关领域：医药卫生更多>>
相关作者：姜申德刘雷柏明祁兴顺陈辉更多>>
相关机构：天津大学河北康泰药业有限公司第四军医大学沈阳药科大学更多>>
相关期刊：《Case Reports in Clinical Medicine》《World Journal of Gastrointestinal Surgery》《国际肿瘤学杂志》《World Journal of Hepatology》更多>>
相关基金：国家自然科学基金国家教育部博士点基金广州市科技计划项目更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Gastric gastrointestinal stromal tumor in a patient with neurofibromatosis type I presenting with anemia:A case report
《World Journal of Gastrointestinal Oncology》2025年第3期394-401,共8页Guang-Yang Bai Ke-Shu Shan Chen-Sheng Li Xiang-Hua Wang Ming-Yang Feng Yan Gao 
BACKGROUND Gastrointestinal stromal tumors(GISTs)are caused by mutations in the KIT and platelet derived growth factor receptor alpha genes in approximately 90%of cases.A minority of wild-type GISTs are associated wit...
关键词：Neurofibromatosis type 1 Gastrointestinal stromal tumors Regorafenib:Anemia Case report 
Electrostatic spraying for fine-tuning particle dimensions to enhance oral bioavailability of poorly water-soluble drugs
《Asian Journal of Pharmaceutical Sciences》2024年第5期139-151,共13页Jung Suk Kim Seunghyun Cheon Mi Ran Woo Sanghyun Woo Jee-Eun Chung Yu Seok Youn Kyung Taek Oh Soo-Jeong Lim Sae Kwang Ku Bao Loc Nguyen Jong Oh Kim Sung Giu Jin Han-Gon Choi 
This work was supported by the National Research Foundation of South Korea(NRF)grants funded by the South Korean government(MEST)(No.2022R1A2C2004197,RS-2024-00407053 and RS-2023-00208448).
While spray-drying has been widely utilized to improve the bioavailability of poorly water-soluble drugs,the outcomes often exhibit suboptimal particle size distribution and large particle sizes,limiting their effecti...
关键词：Electrostatic spray drying Poorly water-soluble drug Regorafenib Particle size distribution Oral bioavailability Oral antitumor efficacy 
COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma
《Acta Biochimica et Biophysica Sinica》2024年第7期997-1010,共14页Shaoqin Zhang Xuezhen Xue Fengdan Chen Yahan Yang Nan Zhang Yan Chen Wenda Wu Jichuang Wang Ning Zheng 
supported by the grants from the Natural Science Foundation of Fujian Province(Nos.2020J01597 and 2021J01695);the Joint Funds for the Innovation of Science and Technology,Fujian Province(No.2020Y9001);the Startup Fund for Scientific Research of High-Level Talent of Fujian Medical University(No.XRCZX2019034).
Systemic therapies,the ultimate strategies for patients with advanced hepatocellular carcinoma(HCC),are suffering from serious clinical challenges,such as the occurrence and development of drug resistance.Treatment re...
关键词：regorafenib resistance hepatocellular carcinoma COL5A2/LIFR axis migration and invasion vasculogenic mimicry 
Efficacy comparison of fruquintinib,regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer
《World Journal of Gastrointestinal Oncology》2024年第6期2449-2462,共14页Tian-Qi An Hui Qiu Quan-Bo Zhou Hong Zong Shuang Hu Yu-Gui Lian Rui-Hua Zhao 
BACKGROUND Regorafenib(R)and fruquintinib(F)are the standard third-line regimens for colorectal cancer(CRC)according to the National Comprehensive Cancer Network guidelines,but both have limited efficacy.Several phase...
关键词：Colorectal cancer Fruquintinib REGORAFENIB Programmed death-1 inhibitor Real-world 
Analysis of efficacy and safety for the combination of regorafenib and PD-1 inhibitor in advanced hepatocellular carcinoma:A real-world clinical study被引量：1
《iLIVER》2024年第2期16-21,共6页Zhongchao Li Jingtao Zhong Chengsheng Zhang Bo Zhang Xuetao Shi Lei Li 
supported by the National Natural Science Foundation of China under contract No.82203000;the Shandong Provincial Natural Science Foundation under contract No.ZR202111120102;the Taishan Scholars Program of Shandong Province(tsqnz20221164).
Background and aims:Hepatocellular carcinoma(HCC)is a prevalent and deadly disease with limited treatment options.Regorafenib,a tyrosine kinase inhibitor,has shown promise in HCC treatment but faces limitations as a m...
关键词：REGORAFENIB PD-1 inhibitor Hepatocellular carcinoma Combination therapy 
Regorafenib对Aβ_(1-42)诱导的阿尔兹海默病细胞与动物模型的保护作用与机制探究被引量：1
《药物生物技术》2023年第5期441-447,共7页黄宏飞 王悦 陈松 高向东 
国家自然科学基金资助项目(No.81872850,No.82073755)。
研究Regorafenib对阿尔兹海默病(Alzheimer’s disease, AD)的保护作用及机制,本研究采用Aβ_(1-42)损伤造模建立AD细胞模型与AD动物模型,并使用Regorafenib进行干预。使用Western blot法、免疫组化以及qRT-PCR法考察Regorafenib对模型...
关键词：阿尔兹海默病 REGORAFENIB AMPK/MEK/ERK通路 TAU蛋白 Β-淀粉样蛋白 炎症因子 
Effects of sorafenib and regorafenib on the expression of hypoxia-inducible factors in hepatocellular carcinoma-transplanted nude mice
《Oncology and Translational Medicine》2022年第5期259-263,共5页Ganxin Wang Bai Wei Qian Ma Shu Huang Qi Wu 
Objective The objective of this study was to investigate the inhibitory effects of sorafenib and regorafenib on the growth of hepatocellular carcinoma(HCC)using a subcutaneous transplantation tumor model in nude mice ...
关键词：SORAFENIB REGORAFENIB liver cancer hypoxia-inducible factor hypoxia-associated factor 
Regorafenib联合PD⁃1抑制剂在晚期微卫星稳定型结直肠癌中的疗效和安全性
《中国癌症防治杂志》2022年第5期521-528,共8页罗茜茜 陈佳梅 石薇 陈永顺 
湖北省中央引导地方科技发展专项项目(ZYYD2020000169)。
目的评估瑞戈非尼(Regorafenib)联合PD-1抑制剂三线及以上治疗晚期微卫星稳定(microsatellite stable,MSS)型结直肠癌(colorectal cancer,CRC)的疗效和安全性。方法选择2019年1月至2022年3月在武汉大学人民医院肿瘤中心接受Regorafenib...
关键词：结直肠癌 REGORAFENIB PD-1抑制剂 微卫星稳定型 疗效 安全性 
Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib:Multicenter French clinical experience in real-life after matching
《World Journal of Gastrointestinal Oncology》2022年第8期1510-1527,共18页Xavier Adhoute Marie De Matharel Laurent Mineur Guillaume Pénaranda Dann Ouizeman Clemence Toullec Albert Tran Paul Castellani Armelle Rollet Valérie Oules HervéPerrier Si Nafa Si Ahmed Marc Bourliere Rodolphe Anty 
BACKGROUND Starting a second-line systemic treatment for hepatocellular carcinoma(HCC)is a common situation.The only therapeutic options in France are two broadspectrum tyrosine kinase inhibitors(TKIs),regorafenib(REG...
关键词：Hepatocellular carcinoma REGORAFENIB Cabozantinib C-reactive protein Neutrophillymphocyte ratio 
Case Report: Bilateral Pneumothoraces due to Targeted Tumor Therapy with Regorafenib in a Young Woman with Metastatic Colorectal Cancer
《Case Reports in Clinical Medicine》2022年第5期139-145,共7页Tobias Rachow Tim Sandhaus Thomas Ernst Helmut Schiffl Susanne M. Lang 
Background: Colorectal cancer is one of the most common cancer types, frequently metastasizing into the lungs. Treatment options have been vastly improved over the last years. With the increasing use of targeted thera...
关键词：REGORAFENIB PNEUMOTHORAX Pulmonary Metastases Colorectal Cancer 
全选清除导出
共4页<1234>
检索报告 对象比较 聚类工具 使用帮助 返回顶部